SLC5A2 and obesity due to melanocortin 4 receptor deficiency: However, while SGLT-2 inhibitors can reduce the risk of kidney failure and cardiovascular events and provide improvements in glycemic control, neither this drug class nor (ns)MRAs markedly address obesity per se.